创新链系列：中国创新药研发投入景气度指标11月跟踪

Investment Rating - The industry investment rating is "Positive" and maintained [11] Core Insights - The financing ecosystem for China's biopharmaceutical industry is gradually entering a positive cycle, driven by the influx of funds from A/H listings and capital increases of innovative drug companies, leading to an improvement in R&D investment sentiment [2][42] - The IPO channels for innovative drugs have widened, with a resurgence in Hong Kong IPOs and improved fundraising conditions for A-share companies, indicating a positive trend in fundraising for R&D investments [6][31] - The amount of biopharmaceutical financing in China is showing signs of recovery, with significant policy support and an increase in investment funds, suggesting a rebound in the financing environment [8][37] Summary by Sections Innovative Drug R&D Investment Sentiment - The trend of key forward-looking indicators suggests that the funding situation for innovative drug companies is becoming more favorable, which is expected to enhance their willingness to invest in R&D [24] - The innovative drug IPO market is experiencing a resurgence, with 17 companies listed in Hong Kong by the end of November 2025, surpassing the total for 2020 [25][27] Fundraising and Financing Trends - The scale of fundraising through IPOs for pharmaceutical companies in Hong Kong has shown significant improvement since April 2025, with notable monthly highs in fundraising amounts [31] - The scale of capital increases for A-share pharmaceutical companies has also been on the rise, with a peak of 3.9 billion yuan in Q3 2025, the highest since Q2 2023 [33] Biopharmaceutical Financing Environment - The total financing amount for China's biopharmaceutical sector reached 1.76 billion USD in Q3 2025, the highest since Q4 2022, indicating a potential bottoming out and recovery in the financing landscape [37] - The amount of upfront payments for external business development (BD) has become a significant source of funding for R&D, with Q3 2025 figures reaching 1.85 billion USD, surpassing the total financing amount for the same period [40]